142 related articles for article (PubMed ID: 37354365)
1. Omidubicel: First Approval.
Heo YA
Mol Diagn Ther; 2023 Sep; 27(5):637-642. PubMed ID: 37354365
[TBL] [Abstract][Full Text] [Related]
2. Hospitalization and Healthcare Resource Utilization of Omidubicel-Onlv versus Umbilical Cord Blood Transplantation for Hematologic Malignancies: Secondary Analysis from a Pivotal Phase 3 Clinical Trial.
Majhail NS; Miller B; Dean R; Manghani R; Shin H; Sivaraman S; Maziarz RT
Transplant Cell Ther; 2023 Dec; 29(12):749.e1-749.e5. PubMed ID: 37703995
[TBL] [Abstract][Full Text] [Related]
3. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
Horwitz ME; Stiff PJ; Cutler C; Brunstein C; Hanna R; Maziarz RT; Rezvani AR; Karris NA; McGuirk J; Valcarcel D; Schiller GJ; Lindemans CA; Hwang WYK; Koh LP; Keating A; Khaled Y; Hamerschlak N; Frankfurt O; Peled T; Segalovich I; Blackwell B; Wease S; Freedman LS; Galamidi-Cohen E; Sanz G
Blood; 2021 Oct; 138(16):1429-1440. PubMed ID: 34157093
[TBL] [Abstract][Full Text] [Related]
4. Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies.
Khera N; Edwards ML; Song Y; Sun R; Manghani R; Shin H; Simantov R; Signorovitch J; Sivaraman S; Gergis U
Adv Ther; 2024 Apr; 41(4):1637-1651. PubMed ID: 38427220
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation with omidubicel in sickle cell disease.
Parikh S; Brochstein JA; Galamidi E; Schwarzbach A; Kurtzberg J
Blood Adv; 2021 Feb; 5(3):843-852. PubMed ID: 33560399
[TBL] [Abstract][Full Text] [Related]
6. Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
Lin C; Sajeev G; Stiff PJ; Brunstein CG; Cutler C; Sanz G; Lindemans CA; Rezvani AR; Hanna R; Koh LP; Maziarz RT; Hwang WYK; Song Y; Liu Q; Manghani R; Sivaraman S; Signorovitch J; Horwitz ME; Sung AD
Transplant Cell Ther; 2023 Jan; 29(1):52.e1-52.e9. PubMed ID: 36179986
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
[TBL] [Abstract][Full Text] [Related]
8. Immune Reconstitution Profiling Suggests Antiviral Protection after Transplantation with Omidubicel: A Phase 3 Substudy.
Szabolcs P; Mazor RD; Yackoubov D; Levy S; Stiff P; Rezvani A; Hanna R; Wagner J; Keating A; Lindemans CA; Karras N; McGuirk J; Hamerschlak N; López-Torija I; Sanz G; Valcarcel D; Horwitz ME
Transplant Cell Ther; 2023 Aug; 29(8):517.e1-517.e12. PubMed ID: 37120136
[TBL] [Abstract][Full Text] [Related]
9. The impact of omidubicel on immune reconstitution and infections in cord blood transplant patients.
De Sa H; Maziarz RT; Gandhi AP
Expert Opin Biol Ther; 2024 Mar; 24(3):139-146. PubMed ID: 38481366
[TBL] [Abstract][Full Text] [Related]
10. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
Horwitz ME; Chao NJ; Rizzieri DA; Long GD; Sullivan KM; Gasparetto C; Chute JP; Morris A; McDonald C; Waters-Pick B; Stiff P; Wease S; Peled A; Snyder D; Cohen EG; Shoham H; Landau E; Friend E; Peleg I; Aschengrau D; Yackoubov D; Kurtzberg J; Peled T
J Clin Invest; 2014 Jul; 124(7):3121-8. PubMed ID: 24911148
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of intensified myeloablative conditioning regime without antithymocytic globulin (ATG) with myeloablative conditioning regime for single-unit unrelated umbilical cord blood transplantation in hematological malignancies].
Sun ZM; Liu HL; Wu Y; Geng LQ; Zheng CC; Tang BL; Zhu XY; Tong J; Wang XB; Ding KY; Wan X; Zhang L; Yao W; Zhang XH; Han YS; Yang HZ; Liu X; Zhu WW; Wu JS; Wang ZY
Zhonghua Yi Xue Za Zhi; 2016 Jul; 96(28):2214-9. PubMed ID: 27480651
[TBL] [Abstract][Full Text] [Related]
12. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
[TBL] [Abstract][Full Text] [Related]
13. Double-unit cord blood transplantation after myeloablative conditioning for patients with hematologic malignancies: a multicenter phase II study in Japan.
Kai S; Wake A; Okada M; Kurata M; Atsuta Y; Ishikawa J; Nakamae H; Aotsuka N; Kasai M; Misawa M; Taniguchi S; Kato S
Biol Blood Marrow Transplant; 2013 May; 19(5):812-9. PubMed ID: 23416856
[TBL] [Abstract][Full Text] [Related]
14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
15. Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Horwitz ME; Wease S; Blackwell B; Valcarcel D; Frassoni F; Boelens JJ; Nierkens S; Jagasia M; Wagner JE; Kuball J; Koh LP; Majhail NS; Stiff PJ; Hanna R; Hwang WYK; Kurtzberg J; Cilloni D; Freedman LS; Montesinos P; Sanz G
J Clin Oncol; 2019 Feb; 37(5):367-374. PubMed ID: 30523748
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
Green MM; Chao N; Chhabra S; Corbet K; Gasparetto C; Horwitz A; Li Z; Venkata JK; Long G; Mims A; Rizzieri D; Sarantopoulos S; Stuart R; Sung AD; Sullivan KM; Costa L; Horwitz M; Kang Y
J Hematol Oncol; 2016 Aug; 9(1):71. PubMed ID: 27535663
[TBL] [Abstract][Full Text] [Related]
17. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.
Sun Z; Liu H; Luo C; Geng L; Zheng C; Tang B; Zhu X; Tong J; Wang X; Ding K; Wan X; Zhang L; Yao W; Song K; Zhang X; Wu Y; Yang H; Han Y; Liu X; Zhu W; Wu J; Wang Z
Int J Cancer; 2018 Aug; 143(3):699-708. PubMed ID: 29473150
[TBL] [Abstract][Full Text] [Related]
18. Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation.
de Koning C; Tao W; Lacna A; van Veghel K; Horwitz ME; Sanz G; Jagasia MH; Wagner JE; Stiff PJ; Hanna R; Cilloni D; Valcárcel D; Peled T; Galamidi Cohen E; Goshen U; Pandit A; Lindemans CA; Jan Boelens J; Nierkens S
Bone Marrow Transplant; 2021 Nov; 56(11):2826-2833. PubMed ID: 34312498
[TBL] [Abstract][Full Text] [Related]
19. Prospective Randomized Study Comparing Myeloablative Unrelated Umbilical Cord Blood Transplantation versus HLA-Haploidentical Related Stem Cell Transplantation for Adults with Hematologic Malignancies.
Sanz J; Montoro J; Solano C; Valcárcel D; Sampol A; Ferrá C; Parody R; Lorenzo I; Montesinos P; Ortí G; Hernández-Boluda JC; Balaguer-Roselló A; Guerreiro M; Carretero C; Sanz GF; Sanz MA; Piñana JL
Biol Blood Marrow Transplant; 2020 Feb; 26(2):358-366. PubMed ID: 31655119
[TBL] [Abstract][Full Text] [Related]
20. Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials.
Lin C; Schwarzbach A; Sanz J; Montesinos P; Stiff P; Parikh S; Brunstein C; Cutler C; Lindemans CA; Hanna R; Koh LP; Jagasia MH; Valcarcel D; Maziarz RT; Keating AK; Hwang WYK; Rezvani AR; Karras NA; Fernandes JF; Rocha V; Badell I; Ram R; Schiller GJ; Volodin L; Walters MC; Hamerschlak N; Cilloni D; Frankfurt O; McGuirk JP; Kurtzberg J; Sanz G; Simantov R; Horwitz ME
Transplant Cell Ther; 2023 May; 29(5):338.e1-338.e6. PubMed ID: 36775201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
